MAL2 and bladder transitional cell carcinoma: The data showed that MAL2 is highly expressed in pan-cancers, including bladder urothelial carcinoma (BLCA), invasive breast carcinoma (BRCA), cervical squamous cell carcinoma (CESC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), OC, pancreatic adenocarcinoma (PAAD), rectal adenocarcinoma (READ), stomach adenocarcinoma (STAD), thymoma (THYM), and uterine corpus endometrial carcinoma (UCEC), and was remarkably upregulated in two cancer types, involving OC and UCEC (Figure 1A).